Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/5na9c493

ADME PROPERTIES OF ALCOHOL AND ITS IMPACT ON THE RESPIRATORY SYSTEM

Dr. Priyanka N[1*], Dr. Kavitha N. S[2], Ms. Afrah Faritha S [3], Ms. Aishwarya M. R. [4], Ms. Aswini R. P.[5], Ms. Tejasri V. S [6]

[1*]Assistant Professor, Department of Pharmacology, GRT Institute of Pharmaceutical Education and Research Tiruttani priyanka213111@gmail.com
[2]Department Of Pharmacy Practice, Jaya College of Pharmacy, Thiruninravur
[3]B. Pharm, GRT Institute of Pharmaceutical Education and Research, Tirutani
[4]B. Pharm, GRT Institute of Pharmaceutical Education and Research, Tirutani
[5]B. Pharm, GRT Institute of Pharmaceutical Education and Research, Tirutani
[6]B. Pharm, GRT Institute of Pharmaceutical Education and Research, Tirutani

***Corresponding Author:** Dr. Priyanka N
*Assistant Professor, Department of Pharmacology, GRT Institute of Pharmaceutical Education and Research Tiruttani priyanka213111@gmail.com

Abstract
Alcohol consumption is a globally prevalent behavior with well-established systemic health consequences. Its effects on the respiratory system remain under-recognized despite growing evidence of mechanistic and clinical significance. This review synthesizes the current understanding of alcohol's pharmacokinetics, including absorption, distribution, metabolism, and excretion (ADME), as well as its role in mediating pulmonary dysfunction. Ethanol and related alcohols alter mucociliary clearance, compromise epithelial integrity, and suppress innate immune responses, enhancing the danger of respiratory infections, acute lung injury, and chronic pulmonary disease. Metabolic byproducts such as acetaldehyde and reactive oxygen species contribute to oxidative stress, mitochondrial damage, and pro-inflammatory cascades in the lung microenvironment. The review also highlights the synergistic impact of alcohol with other respiratory risk factors, including tobacco and environmental exposures. Clinical implications include underdiagnosed alcohol-related respiratory impairment, worse outcomes in critical care settings, and the need for targeted screening. Key research gaps are identified, including the lack of longitudinal studies, limited translational models, and underutilization of precision medicine frameworks. Future directions emphasize the importance of integrative, genotype-informed research to inform prevention and personalized management strategies. Addressing alcohol's impact on respiratory health is essential to mitigating preventable disease burden worldwide.

Keywords: Alcohol metabolism, Respiratory system, Oxidative stress, Immune dysfunction, Pulmonary injury

1. Introduction

Alcohols, a group of organic substances that have at least one hydroxyl (-OH) functional groups attached to saturated carbon atoms, are widely encountered in both clinical and non-clinical contexts.[1] Among the commonly studied alcohols, ethanol (C_2H_5OH) is the predominant psychoactive substance

consumed globally, while methanol (CH_3OH) and isopropanol (C_3H_7OH) serve primarily as industrial solvents and disinfectants.[2] These alcohols differ markedly in their pharmacokinetic profiles and toxicological impacts, with ethanol being the sole variant sanctioned for human consumption. The systemic and organ-specific effects of these agents are mediated by their Absorption, Distribution, Metabolism, and Excretion (ADME) characteristics, which govern their bioavailability, site of action, and potential for toxicity.[3]

Globally, alcohol consumption remains pervasive, with the World Health Organization reporting that over 2.3 billion individuals consume alcohol, contributing to more than 3 million deaths annually, representing nearly 5.3% of all global fatalities.[4] Traditionally, research has focused on the hepatic, neurological, and cardiovascular consequences of chronic alcohol use. Accumulating evidence indicates that the respiratory system is also a critical, but under-recognized, target of alcohol-induced pathophysiology.[5] Both acute and chronic exposure to ethanol and its metabolites have been implicated in disrupting pulmonary immune defense, impairing mucociliary clearance, altering airway reactivity, and exacerbating susceptibility to infections such as pneumonia and tuberculosis.[6]

Understanding the ADME dynamics of alcohol is essential for elucidating its diverse respiratory effects. Ethanol, for instance, is rapidly absorbed through the gastrointestinal tract, distributed widely across total body water, metabolized primarily via alcohol dehydrogenase (ADH) and the microsomal ethanol oxidizing system (MEOS), and partially excreted via the lungs.[7] This pulmonary exhalation forms the basis of breath alcohol testing, but also signifies a direct interface between alcohol pharmacokinetics and respiratory exposure.[8] Chronic alcohol use has been linked to "alcohol-induced lung injury," characterized by oxidative stress, surfactant dysfunction, and compromised alveolar-capillary integrity.[9]

Given the multidimensional effect of alcohol on respiratory health and the pivotal role of its ADME behavior in modulating these outcomes, a comprehensive synthesis is warranted. This review aims to critically examine the ADME profiles of ethanol, methanol, and isopropanol, and to delineate their mechanistic and clinical impacts on the respiratory system. Particular emphasis is placed on pulmonary pharmacokinetics, immune modulation, epidemiological correlations, and the implications for critical care, especially in alcohol-exposed patients requiring ventilatory support. By bridging pharmacological principles with pulmonary pathophysiology, this review endeavors to illuminate an often-overlooked dimension of alcohol-related harm and stimulate further translational and clinical inquiry.

2. Pharmacokinetics of Alcohol: ADME Overview

The pharmacokinetic behavior of alcohols, including ethanol, methanol, and isopropanol, forms the physiological basis for their diverse effects across organ systems, including the respiratory tract.[10] The ADME (Absorption, Distribution, Metabolism, and Excretion) framework offers a structured approach for understanding how these compounds enter, circulate, undergo biotransformation, and are eliminated from the body. While ethanol remains the most commonly consumed form, methanol and isopropanol are encountered primarily through industrial, accidental, or intentional exposures.[11] Their differential ADME characteristics account for distinct toxicodynamic outcomes, influencing both clinical presentation and therapeutic management.

2.1 Absorption

All three alcohols are absorbed via passive diffusion, driven by their low molecular weight and high aqueous solubility. Ethanol absorption occurs primarily in the stomach (20%) and small intestine (80%), with the latter serving as the predominant site due to its large surface area and rich vascularization.[12] Methanol and isopropanol are mainly absorbed through the small intestine following ingestion.[13]

Numerous factors affect the rate and degree of absorption, including gastric emptying, the presence of food, alcohol concentration, and individual physiology. Food delays ethanol absorption by prolonging gastric retention, whereas carbonated beverages enhance absorption by promoting gastric motility.[14] Optimal absorption occurs at ethanol concentrations of 15–30%, while highly concentrated

or diluted forms may irritate the gastric mucosa or slow transit. Sex-related differences also exist, with females often exhibiting higher blood alcohol concentrations (BAC) due to lower gastric ADH activity and reduced total body water content.[15]

2.2 Distribution

Once absorbed, alcohols are distributed rapidly throughout the body's water compartments. Ethanol exhibits a volume of distribution (V_d) ranging from 0.6 to 0.7 L/kg, reflecting its preferential localization in aqueous tissues such as blood, cerebrospinal fluid, and alveolar lining fluid.[16] Methanol, with a slightly higher V_d (~0.77 L/kg), achieves wider tissue penetration, while isopropanol distributes similarly to ethanol (V_d ~0.6 L/kg).[17]

Due to their lipophilicity and small molecular size, alcohols traverse biological barriers with ease. Ethanol readily crosses the blood–brain barrier, accounting for its central nervous system effects, and the placenta, leading to potential teratogenic outcomes such as fetal alcohol spectrum disorders (FASDs).[18] Importantly, ethanol and other alcohols can also permeate alveolar tissues via the systemic circulation and exhaled air, potentially modulating local immune responses and contributing to direct pulmonary epithelial injury.

2.3 Metabolism

The metabolic fate of alcohols differs considerably across compounds, although oxidation via dehydrogenase enzymes remains a common feature. In humans, ethanol is primarily metabolized in the liver by ADH into acetaldehyde, a reactive intermediate that is subsequently converted to acetate by ALDH.[19] In chronic alcohol users or under high-dose conditions, the microsomal ethanol oxidizing system (MEOS), involving the CYP2E1 isoenzyme, becomes increasingly relevant. A minor contribution is made by catalase, particularly in extrahepatic tissues.[20]

Genetic polymorphisms within ADH and ALDH significantly influence metabolic efficiency. For example, the ADH1B*2 variant is associated with increased ethanol oxidation, while the ALDH2*2 allele, common in East Asian populations, results in reduced acetaldehyde clearance and pronounced toxic effects after alcohol consumption.[21]

Methanol metabolism also begins with ADH, forming formaldehyde, which is rapidly oxidized to formic acid, the principal agent responsible for methanol-induced ocular and central nervous system toxicity. Isopropanol is oxidized by ADH to acetone, a relatively inert metabolite with lesser toxicity but substantial CNS depressant properties at high concentrations.[22]

2.4 Excretion

Although the majority of alcohol undergoes hepatic metabolism, a proportion is excreted unchanged, providing diagnostic utility and indicating potential routes for tissue interaction.[23] Ethanol is eliminated through renal (urine), pulmonary (exhaled air), and dermal (sweat) pathways. The pulmonary route, in particular, has clinical significance both as a diagnostic modality (i.e., breathalyzers) and as a potential contributor to direct lung epithelial exposure [24]

Ethanol follows zero-order kinetics, where elimination occurs at a fixed rate (~10 mL/hour), independent of concentration, an unusual pharmacokinetic property attributable to enzyme saturation.[25] This results in a plasma half-life of approximately 4–6 hours, though it may vary depending on metabolic capacity and genetic background. Methanol displays a prolonged half-life (12–20 hours), especially when ADH is inhibited (e.g., by fomepizole), prolonging systemic exposure to toxic metabolites.[26] Isopropanol exhibits a shorter half-life of 2.5–3 hours, with renal impairment potentially delaying clearance. A comparative summary of the key ADME properties of ethanol, methanol, and isopropanol is presented in Table 1. This consolidated overview highlights the pharmacokinetic distinctions that underlie their differential toxicity profiles and clinical implications.

Table 1. Comparative ADME Parameters of Common Alcohols

Parameter	Ethanol	Methanol	Isopropanol
Primary Absorption Site	Stomach & Small Intestine	Small Intestine	Small Intestine
Time to Peak (T_{max})	30–120 minutes	60–90 minutes	30–60 minutes
Volume of Distribution	0.6–0.7 L/kg	0.77 L/kg	0.6 L/kg
Major Metabolic Pathway	ADH → Acetaldehyde → Acetate	ADH → Formaldehyde → Formic Acid	ADH → Acetone
Toxic Metabolites	Acetaldehyde (moderately toxic)	Formic Acid (highly toxic)	Acetone (low toxicity)
Elimination Routes	Urine, Breath, Sweat	Urine, Breath	Urine, Breath
Plasma Half-life	4–6 hours	12–20 hours	2.5–3 hours

3. Alcohol and the Respiratory System

Alcohol exerts a significant influence on multiple organ systems, but its role in impairing respiratory function is increasingly recognized as both clinically relevant and mechanistically complex.[27] While traditionally underappreciated, evidence now supports that alcohol, particularly ethanol, interacts with the respiratory system not only through systemic circulation but also via direct pulmonary exposure through inhaled and exhaled metabolites. These interactions occur acutely through neural and muscular effects on breathing, and chronically, via cellular and immunological changes within the lung parenchyma and airways.[28] This section systematically explores the acute and chronic consequences of alcohol on respiratory physiology, alongside its synergy with other respiratory insults such as smoking and chronic pulmonary disease.

3.1 Acute Effects

Central Respiratory Depression

One of the most immediate effects of acute alcohol consumption is depression of the central nervous system, particularly the brainstem respiratory centers.[29] Ethanol enhances γ-aminobutyric acid neurotransmission and inhibits N-methyl-D-aspartate receptor activity, leading to dose-dependent depression of ventilatory drive. At moderate levels, this results in reduced tidal volume and blunted responsiveness to hypercapnia and hypoxia. At toxic concentrations, alcohol can induce profound respiratory depression, culminating in hypoventilation, hypoxemia, and potentially respiratory arrest.[30]

Sleep-Disordered Breathing

Alcohol has a well-documented impact on sleep architecture and upper airway physiology. It reduces the tone of pharyngeal dilator muscles, particularly the genioglossus, thereby promoting airway collapsibility during sleep.[31] This mechanism exacerbates obstructive sleep apnea (OSA), particularly in individuals predisposed by obesity, craniofacial structure, or upper airway inflammation. Research has revealed that alcohol ingestion before bedtime increases the frequency and duration of apneic episodes, lowers nocturnal oxygen saturation, and disrupts normal sleep cycles by increasing arousals and reducing REM sleep.[32]

Impairment of Airway Reflexes

Ethanol acutely impairs protective airway reflexes such as coughing and swallowing by desensitizing sensory receptors and inhibiting brainstem integration. This suppression significantly elevates the risk of aspiration, particularly during episodes of emesis or altered consciousness.[33] Alcohol inhibits the mucociliary escalator, a primary defense mechanism in the respiratory tract, by disrupting ciliary

motility and epithelial integrity.[34] These impairments raise the possibility of infections of the lower respiratory tract and aspiration pneumonia, particularly in intoxicated individuals.

3.2 Chronic Effects

The Alcoholic Lung Phenotype

Chronic alcohol consumption leads to a constellation of pulmonary alterations now referred to as the "alcoholic lung" phenotype.[35] These changes include increased alveolar epithelial permeability, surfactant dysfunction, reduced antioxidant defenses, and altered pulmonary macrophage activity. Long-term alcohol exposure induces oxidative stress within the lung, primarily via ethanol metabolism by cytochrome P450 2E1 and generation of ROS.[36] The resulting oxidative burden compromises epithelial tight junctions, disrupts alveolar-capillary barrier function, and increases pulmonary susceptibility to environmental insults.

Increased Susceptibility to Infection

Chronic alcohol use has been robustly related to a heightened risk of respiratory infections. Ethanol impairs both innate and adaptive immune responses in the lung. Macrophages exhibit reduced phagocytic capacity, while neutrophil recruitment and function are compromised.[37] Alveolar macrophages show a blunted response to lipopolysaccharide, a key microbial pattern recognition signal, and fail to upregulate pro-inflammatory cytokines effectively. These alterations contribute to an increased incidence and severity of pneumonia, including community-acquired and ventilator-associated forms. Alcohol-related immune suppression contributes to greater susceptibility to Mycobacterium tuberculosis, with epidemiological studies confirming a two- to three-fold higher risk among chronic users.[38]

Pulmonary Inflammation and Remodeling

Beyond infection, chronic ethanol exposure promotes low-grade pulmonary inflammation and fibrotic remodeling. Alcohol increases the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 within lung tissues.[39] It also disrupts surfactant production and turnover, compromising alveolar stability and contributing to atelectasis and ventilation-perfusion mismatch. Animal studies have demonstrated that prolonged intake of alcohol exacerbates pulmonary fibrosis following secondary insults, such as bleomycin exposure, indicating a role in disease progression.[40]

3.3 Interaction with Other Respiratory Risk Factors

Alcohol and Tobacco Synergism

Alcohol and tobacco are often co-consumed, and their combined effects on the respiratory system are synergistically deleterious.[41] Both agents generate reactive oxygen species and impair mucociliary clearance, but together, they amplify inflammatory signaling and epithelial injury. Tobacco smoke enhances ethanol-induced CYP2E1 expression, potentiating oxidative metabolism and ROS production, as illustrated in Figure 1. Alcohol may increase the bioavailability of carcinogens present in tobacco by altering mucosal permeability and glutathione buffering.[42] Clinical data suggest that individuals who smoke and consume alcohol excessively are at disproportionately higher risk for chronic bronchitis, emphysema, and lung cancer.

Occupational and Environmental Exposures

Individuals with prolonged alcohol use may also be more vulnerable to occupational and environmental respiratory hazards. Ethanol-induced impairments in pulmonary barrier integrity and immune function render the lungs more susceptible to particulates, toxic fumes, and microbial pathogens encountered in settings such as construction, mining, and chemical manufacturing.[43] For example, studies have noted elevated rates of pneumoconiosis and hypersensitivity pneumonitis in alcohol users with occupational exposures compared to non-users.[44]

Impact on Comorbid Pulmonary Diseases

Alcohol use significantly exacerbates outcomes in patients with pre-existing respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and, more recently, COVID-19.[45] In asthma, alcohol-induced inflammation may potentiate bronchial hyperreactivity, although the literature remains mixed. In COPD, alcohol use correlates with increased exacerbation rates, poorer pulmonary function, and worse quality-of-life indices. During the COVID-19 pandemic, alcohol consumption surged globally, raising concerns about its impact on respiratory morbidity. Alcohol-induced immune dysfunction and impaired mucosal defense may facilitate viral invasion, increase viral shedding, and worsen disease severity, especially in patients requiring mechanical ventilation.[46]



Figure 1. Pathophysiological Mechanisms Linking Chronic Alcohol Use to Respiratory Dysfunction

4. Alcohol-Induced Oxidative Stress and Respiratory Immunosuppression

Chronic alcohol consumption is increasingly implicated in the disruption of pulmonary immune function through mechanisms rooted in oxidative stress and cellular immune dysregulation.[47] These effects, while subtle in early exposure, accumulate progressively and compromise the lung's ability to defend against pathogens, respond to injury, and maintain structural integrity. The respiratory system, especially the alveolar epithelium and resident immune cells, becomes a vulnerable target in individuals with sustained alcohol use, particularly those with comorbid respiratory disease or critical illness requiring ventilatory support.[48]

4.1 Oxidative Stress and Reactive Oxygen Species Generation

One of the principal biochemical pathways through which alcohol inflicts pulmonary damage is the generation of ROS. Ethanol is primarily metabolized in the liver via alcohol dehydrogenase, but chronic exposure induces the microsomal ethanol-oxidizing system, specifically the cytochrome P450 2E1 (CYP2E1) isoform, which generates substantial quantities of ROS as byproducts of ethanol oxidation.[49] CYP2E1 is also expressed in the pulmonary epithelium and macrophages, thus contributing to localized oxidative stress within the lungs.

These ROS, including superoxide anions, hydrogen peroxide, and hydroxyl radicals, inflict damage on lipids, proteins, and DNA.[50] They disrupt the lipid bilayer of alveolar epithelial cells, enhance permeability of the alveolar-capillary barrier, and contribute to loss of surfactant integrity, essential for alveolar expansion. Mitochondrial ROS production is also exacerbated in chronic alcohol users, leading to mitochondrial DNA damage and bioenergetic failure in lung tissue.

Further compounding this imbalance is a reduction in antioxidant defenses, such as glutathione, superoxide dismutase, and catalase. Glutathione depletion is especially prominent in the alveolar epithelial lining fluid of individuals with alcohol use disorder (AUD), making their lungs more susceptible to oxidative injury from secondary insults, such as infection or mechanical ventilation.[51]

4.2 Mitochondrial Dysfunction in Airway Epithelium

Mitochondria play a central role in redox homeostasis and immune signaling within the lung.[52] Chronic ethanol exposure alters mitochondrial structure, impairs electron transport chain activity, and promotes mitochondrial permeability transition pore opening. These disruptions trigger the release of pro-apoptotic factors such as cytochrome c and increase susceptibility to epithelial apoptosis. This is especially relevant in the type II alveolar cells, which are essential for surfactant production and alveolar repair after injury.

Mitochondrial dysfunction also reduces the production of ATP, impairing processes such as ciliary beating, active ion transport, and surfactant secretion.[53] This results in impaired mucociliary clearance and an elevated risk of pathogen colonization. Thus, the metabolic footprint of chronic alcohol exposure extends beyond systemic toxicity to directly compromise epithelial resilience and host defense.[54]

4.3 Impaired Neutrophil and Macrophage Function

Neutrophils and alveolar macrophages are frontline defenders of pulmonary immunity. Chronic ethanol ingestion attenuates their recruitment, chemotaxis, phagocytosis, and oxidative burst capacity.[55] Alveolar macrophages from alcohol-exposed individuals demonstrate a blunted response to Toll-like receptor (TLR) stimulation, leading to reduced secretion of pro-inflammatory cytokines and chemokines.[56] This renders the host less capable of clearing bacterial, viral, and fungal pathogens from the lower respiratory tract.

In neutrophils, alcohol suppresses NADPH oxidase activation, diminishing the production of microbicidal ROS during the respiratory burst. It also impairs actin polymerization and intracellular signaling necessary for effective phagocytosis. These effects compromise microbial clearance, elevate pathogen burden, and allow for unchecked infection that may progress to acute lung injury or acute respiratory distress syndrome, particularly in the context of pneumonia or sepsis.[57]

4.4 Altered Cytokine and Inflammatory Profiles

Ethanol has profound effects on pulmonary cytokine networks, skewing the balance toward immunosuppression or maladaptive inflammation. In macrophages, alcohol downregulates the production of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-12 (IL-12), impairing macrophage activation and T-helper 1 (Th1) responses.[58] This suppresses antigen presentation and the initiation of adaptive immunity. In parallel, interleukin-10 (IL-10), an anti-inflammatory cytokine, is often upregulated, further dampening the immune response.[59]

During infection or tissue injury, the dysregulated cytokine environment may delay the resolution of inflammation or promote persistent tissue damage. The lungs of chronic alcohol users often exhibit aberrant NF-κB activation, leading to elevated baseline inflammation and epithelial dysfunction even in the absence of active infection.[60] These mechanisms result in a lung environment that is less responsive to microbial threat and more prone to sustained injury and fibrosis.

4.5 Immunological Consequences: Increased Susceptibility and Severity

The immunosuppressive effects of chronic alcohol exposure translate clinically into increased susceptibility to lower respiratory tract infections, such as Streptococcus pneumoniae, Haemophilus influenzae, and Mycobacterium tuberculosis.[61] Patients with alcohol use disorder are more likely to develop severe pneumonia, require ICU admission, and experience prolonged hospital stays, as illustrated in Figure 2. Furthermore, once infected, they exhibit worse outcomes, with a higher risk of developing ARDS, requiring mechanical ventilation, and facing increased mortality.

The intersection of oxidative stress and immune dysfunction is particularly serious in critical care settings. Alcohol-induced lung injury impairs the efficacy of interventions such as positive pressure ventilation and antibiotic therapy.[62] The pro-oxidative, pro-apoptotic milieu created by chronic alcohol exposure may predispose to ventilator-induced lung injury (VILI) by amplifying mechanical stress responses.



Figure 2. Alcohol-Induced Immunosuppressive Cascade in the Lungs

As illustrated in Figure 2, chronic alcohol use initiates a cascade of pathophysiological events beginning with ROS generation and mitochondrial dysfunction, leading to impaired function of macrophages and neutrophils, altered cytokine signaling, and ultimately heightened vulnerability to pulmonary infection and injury. This cascade, both biochemical and cellular, encapsulates the converging mechanisms through which alcohol undermines pulmonary defense.

5. Clinical and Public Health Implications

The intersection between chronic alcohol consumption and respiratory health carries significant clinical and public health ramifications. As the physiological and immunological effects of alcohol on pulmonary function become more clearly defined, their translation into diagnostic, therapeutic, and preventive strategies assumes growing urgency.[63] Clinicians and health systems must increasingly recognize alcohol use as a modifiable risk factor in respiratory disease management and public health programming.

5.1 Diagnostic and Screening Considerations

One of the major challenges in clinical settings is the underdiagnosis of alcohol-induced respiratory dysfunction. Many symptoms associated with alcohol-related pulmonary compromise, such as dyspnea, cough, or fatigue, are nonspecific and overlap with other respiratory or systemic illnesses.[64]

Patients with alcohol use disorder (AUD) may underreport their consumption, and alcohol-related lung pathology often lacks distinctive radiographic or histological hallmarks.

Given these limitations, systematic screening for alcohol use in patients presenting with respiratory symptoms, particularly in emergency or critical care settings, is vital. Incorporating validated tools such as the Alcohol Use Disorders Identification Test into routine respiratory assessments can help detect at-risk individuals early.[65] Clinicians must maintain a high index of suspicion for alcohol-related lung injury in patients with unexplained hypoxemia, recurrent pneumonia, or poor response to standard therapies.

5.2 Clinical Manifestations and ICU Outcomes

Alcohol-related respiratory pathology spans both acute and chronic domains. Acutely, ethanol's central depressant effects can induce hypoventilation and impair protective reflexes, predisposing individuals to aspiration and infection. Chronic, sustained alcohol use leads to impaired mucociliary clearance, alveolar epithelial dysfunction, and immune suppression factors that raise the risk and severity of lower respiratory tract infections and ARDS.[66]

These clinical manifestations are summarized in Table 2, which delineates key alcohol-related pulmonary impairments across timeframes and associated risk factors. For instance, ARDS is notably associated with both acute intoxication and chronic exposure, especially among ICU patients requiring ventilatory support.[67] Similarly, pneumonia occurs predominantly with chronic use and is strongly associated with smoking and immunosuppression. Impaired mucociliary clearance, common to both acute and chronic alcohol exposure, is nearly universal among habitual users and contributes to frequent infections and delayed pulmonary recovery.[68]

Table 2. Clinical Manifestations of Alcohol-Related Respiratory Impairments

Manifestation	Acute Use	Chronic Use	Risk Factors
Hypoventilation	Present	Not typically observed	Dose-dependent
Acute Respiratory Distress Syndrome (ARDS)	Present	Present	ICU patients
Pneumonia	Not typically observed	Present	Smoking, immunosuppression
Impaired Mucociliary Clearance	Present	Present	All users

These manifestations have profound implications in critical care environments. Studies consistently show that individuals with AUD are more likely to develop severe pneumonia, require intubation, and exhibit higher rates of ventilator-associated complications. Once intubated, they are at increased risk for ventilator-induced lung injury (VILI) due to compromised epithelial and surfactant integrity.[69] The presence of alcohol-induced immunosuppression may blunt febrile and inflammatory responses, delaying recognition and escalation of care.

5.3 Public Health Strategies and Preventive Interventions

At the population level, addressing alcohol-related respiratory impairment requires integrated public health approaches. Given the high co-occurrence of alcohol and tobacco use, dual-exposure mitigation strategies, including taxation, smoking cessation programs, and alcohol reduction campaigns, can significantly reduce respiratory morbidity.[70] Such strategies are especially pertinent in vulnerable populations, including individuals experiencing homelessness, those with psychiatric comorbidities, and incarcerated individuals, where rates of dual use are markedly higher.

Targeted educational campaigns should raise awareness among both healthcare providers and the public about the pulmonary risks of excessive alcohol consumption, beyond its widely known hepatic and neurological consequences. Screening programs in primary care and community health settings can be coupled with brief interventions or referrals for alcohol cessation support.[71]

6. Limitations and Future Directions

Despite growing evidence linking chronic alcohol consumption to respiratory dysfunction, significant knowledge gaps continue to limit clinical translation and mechanistic clarity. Addressing these limitations is essential for refining risk stratification, advancing targeted interventions, and reducing alcohol-related pulmonary morbidity. This section outlines key limitations in the existing literature and proposes strategic directions for future research.

6.1 Key Limitations in Current Research

Lack of Longitudinal Human Studies

Most available data are derived from cross-sectional or retrospective analyses, which limit the ability to establish causality or capture the trajectory of pulmonary decline in individuals with alcohol use disorder. As a result, the natural history of alcohol-induced respiratory compromise remains poorly defined.[72]

Inadequate Translational Animal Models

Existing preclinical models often fail to replicate the complex behavioral, nutritional, and environmental context of chronic alcohol use in humans. They typically neglect factors such as intermittent binge patterns, co-exposure to tobacco smoke, and micronutrient deficiencies, which are common in real-world populations.[73]

Underutilization of Genetic and Immunophenotypic Profiling

Host genetic factors, including polymorphisms in ADH and ALDH enzymes, and individual immune signatures likely contribute to variable pulmonary outcomes in alcohol users. These parameters remain insufficiently integrated into both clinical and preclinical research paradigms.[74]

6.2 Future Research Priorities

Initiate Longitudinal, Multi-Center Human Cohorts

Well-powered, prospective studies should be established to monitor alcohol exposure and pulmonary endpoints over time. These cohorts should incorporate biomarker profiling, lung imaging, and functional respiratory assessments to elucidate early indicators of disease progression.[75]

Develop Multidimensional Experimental Models

Future animal studies must simulate human-relevant patterns of alcohol use, accounting for comorbid risk factors and environmental exposures. Incorporating dietary modulation, episodic ethanol exposure, and co-inhalant exposures will improve the external validity of experimental findings.[76]

Integrate Precision Medicine Frameworks

Incorporating genomic, transcriptomic, and immunophenotypic data into alcohol-lung research could enable personalized risk prediction and therapeutic stratification. Identification of high-risk genotypes or immune endotypes could inform tailored intervention strategies.[77]

7. Conclusion

The pharmacokinetic behavior of alcohol encompassing its absorption, distribution, metabolism, and excretion (ADME) forms the mechanistic basis for its systemic and organ-specific toxicities. Within the respiratory system, these ADME properties facilitate both direct pulmonary exposure via exhalation and indirect injury through systemic circulation, oxidative stress, and immune dysregulation. Ethanol's capacity to impair mucociliary clearance, disrupt epithelial barriers, and suppress alveolar immune function underscores its role in increasing susceptibility to respiratory infections, acute lung injury, and chronic pulmonary conditions. Its metabolic byproducts, particularly acetaldehyde and reactive oxygen species, further exacerbate inflammatory and fibrotic pathways within the lung microenvironment. Despite accumulating evidence, alcohol remains an under-recognized contributor to respiratory disease burden. Future research must prioritize longitudinal

clinical studies, advanced preclinical modeling, and precision medicine approaches to uncover population-specific vulnerabilities and intervention targets. Understanding the genetic, immunologic, and metabolic modifiers of alcohol-induced pulmonary dysfunction will be critical in shaping individualized treatment strategies. From a clinical and public health perspective, systematic screening for alcohol use in patients with respiratory conditions is imperative. Public health policies should address co-exposures such as tobacco and occupational hazards, while also promoting clinician education on alcohol-related pulmonary risks. Integrating molecular insights with epidemiological surveillance will be key to reducing preventable respiratory morbidity and mortality attributable to alcohol. The interplay between alcohol pharmacokinetics and respiratory pathophysiology presents an important but underexplored domain with significant translational and preventive potential. Bridging this gap demands interdisciplinary collaboration across research, clinical, and policy spheres.

References

1. Manglik MR. Biomedical Chemistry-Current Trends and Developments. EduGorilla Publication; 2024 Jul 30.
2. Vel SM, Chandru R, Dhanalakshmi K, et al. Step toward Sustainability: Fuel Production and Hybrid Vehicles. InWaste to Profit 2023 Jun 19 (pp. 335-347). CRC Press.
3. Javdan B. *Drug Metabolism by the Human Gut Microbiome: An Investigation of Metabolic Capacity, Interpersonal Variability, and Genetic Mechanisms* (Doctoral dissertation, Princeton University).
4. World Health Organization. Global status report on alcohol and health and treatment of substance use disorders. World Health Organization; 2024 Jun 25.
5. Chen CH, Ferreira JC, Gross ER, et al. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiological reviews. 2014 Jan;94(1):1-34.
6. Simet SM, Sisson JH. Alcohol's effects on lung health and immunity. Alcohol research: current reviews. 2015;37(2):199.
7. Rajendram R, Rajendram R, Preedy VR. Ethanol metabolism and implications for disease. InNeuropathology of Drug Addictions and Substance Misuse 2016 Jan 1 (pp. 377-388). Academic Press.
8. Jones AW. Alcohol, its absorption, distribution, metabolism, and excretion in the body, and pharmacokinetic calculations. Wiley Interdisciplinary Reviews: Forensic Science. 2019 Sep;1(5):e1340.
9. Jeffers, L. *Chronic Alcohol Consumption Induces Alveolar Epithelial Barrier Dysfunction In Vivo* (Doctoral dissertation, Emory University).
10. Clewell III HJ, Gentry PR, Gearhart JM, Covington TR, Banton MI, Andersen ME. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicological Sciences. 2001 Oct 1;63(2):160-72.
11. Rosano TG, DABCC D. Volatile Alcohols: Ethanol, Methanol, and Isopropanol. In Toxicology Laboratory (Contemporary Practice of Poisoning Evaluation) 2001 (p. 173).
12. Butts M, Sundaram VL, Murughiyan U, et al. The influence of alcohol consumption on intestinal nutrient absorption: a comprehensive review. Nutrients. 2023 Mar 24;15(7):1571.
13. Inman B, Maddry JK, Ng PC, et al. High-risk and low-prevalence diseases: Toxic alcohol ingestion. The American Journal of Emergency Medicine. 2023 May 1;67:29-36.
14. Grad S, Abenavoli L, Dumitrascu DL. The Effect of Alcohol on Gastrointestinal Motility. Rev Recent Clin Trials. 2016;11(3):191-5. doi: 10.2174/1574887111666160815103251. PMID: 27527893.
15. Eaton SE, Jagielo-Miller JE, Prendergast MA, et al. Sex differences in alcohol dehydrogenase levels (ADH) and blood ethanol concentration (BEC) in Japanese quail. Poultry Science. 2022 May 1;101(5):101790.
16. Zekan P, Ljubičić N, Blagaić V, et al. Pharmacokinetic analysis of ethanol in a human study: a new modification of a mathematical model. Toxics. 2023 Sep 20;11(9):793.

17. Jones AW, Musshoff F, Krämer T, et al. Toxicology of Specific Substances. Handbook of Forensic Medicine. 2022 Jun 27;2:1167-312.
18. Popova S, Charness ME, Burd L, et al. Fetal alcohol spectrum disorders. Nature reviews Disease primers. 2023 Feb 23;9(1):11.
19. Waddell J, McKenna MC, Kristian T. Brain ethanol metabolism and mitochondria. Current topics in biochemical research. 2022;23:1.
20. Blackmore LJ. *Cellular immune responses to alcohol dehydrogenase and defective immune regulation in severe alcohol-related liver* (Doctoral dissertation, King's College London).
21. Chen CH, Kraemer BR, Mochly-Rosen D. ALDH2 variance in disease and populations. Disease models & mechanisms. 2022 Jun 1;15(6):dmm049601.
22. To ND, Theruvathu JA. Determination and quantification of acetaldehyde, acetone, and methanol in hand sanitizers using headspace GC/MS: effect of storage time and temperature. International Journal of Environmental Research and Public Health. 2024 Jan 9;21(1):74.
23. Goldman MR, Molina-Castro M, Etkins JC, et al. Recent advances in alcohol metabolism: from the gut to the brain. Physiological Reviews. 2025 Jul 10.
24. Georgakopoulou VE, Spandidos DA, Corlateanu A. Diagnostic tools in respiratory medicine. Biomedical Reports. 2025 May 8;23(1):112.
25. O'Donnell JJ, O'Donnell JT, Juettner V. General Principles of Pharmacology. InO'Donnell's Drug Injury 2026 (pp. 209-234). CRC Press.
26. Alrashed M, Aldeghaither NS, Almutairi SY, et al. The perils of methanol exposure: insights into toxicity and clinical management. Toxics. 2024 Dec 20;12(12):924.
27. Odriozola A, Santos-Laso A, Del Barrio M, et al. Fatty liver disease, metabolism and alcohol interplay: a comprehensive review. International Journal of Molecular Sciences. 2023 Apr 24;24(9):7791.
28. Van der Merwe D. Respiratory toxicity. In Veterinary Toxicology 2025 Jan 1 (pp. 185-196). Academic Press.
29. Wolfe M, Menon A, Oto M, et al. Alcohol and the central nervous system. Practical Neurology. 2023 Aug 1;23(4):273-85.
30. Kaya-Akyüzlü D. Genetics and Epigenetics of Alcohol Use Disorder. In The Palgrave Encyclopedia of Disability 2024 Aug 20 (pp. 1-12). Cham: Springer Nature Switzerland.
31. Avraam J, Dawson A, Nicholas CL, et al. Influence of alcohol on genioglossus single motor units in men and women during wakefulness. Experimental Physiology. 2023 Mar;108(3):491-502.
32. Greenlund IM, Cunningham HA, Tikkanen AL, et al. Morning sympathetic activity after evening binge alcohol consumption. American Journal of Physiology-Heart and Circulatory Physiology. 2021 Jan 1;320(1):H305-15.
33. Sato Y, Sugiyama Y, Ishida T, et al. The Potential Role of Oxidative Stress in Modulating Airway Defensive Reflexes. Antioxidants. 2025 May 9;14(5):568.
34. Adivitiya, Kaushik MS, Chakraborty S, et al. Mucociliary respiratory epithelium integrity in molecular defense and susceptibility to pulmonary viral infections. Biology. 2021 Jan 29;10(2):95.
35. Karkoulias K, Tsitsaras H, Patouchas D, et al. The alcoholic lung disease: historical background and clinical features. Medicina. 2008 Sep;44(9):651.
36. Harjumäki R, Pridgeon CS, Ingelman-Sundberg M. CYP2E1 in alcoholic and non-alcoholic liver injury. Roles of ROS, reactive intermediates, and lipid overload. International journal of molecular sciences. 2021 Jul 30;22(15):8221.
37. Hulsebus HJ, Najarro KM, McMahan RH, et al. Ethanol intoxication impairs respiratory function and bacterial clearance and is associated with neutrophil accumulation in the lung after Streptococcus pneumoniae infection. Frontiers in Immunology. 2022 May 4;13:884719.
38. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. European Respiratory Journal. 2017 Jul 13;50(1).
39. Mörs K, Hörauf JA, Kany S, et al. Ethanol decreases inflammatory response in human lung epithelial cells by inhibiting the canonical NF-kB pathway. Cellular Physiology and Biochemistry. 2017 Oct 17;43(1):17-30.

40. Liu T, De Los Santos FG, Phan SH. The bleomycin model of pulmonary fibrosis. InFibrosis: Methods and Protocols 2017 Aug 24 (pp. 27-42). New York, NY: Springer New York.
41. Giorgetti A, Orazietti V, Busardo FP, et al. Psychomotor performances relevant for driving under the combined effect of ethanol and synthetic cannabinoids: A systematic review. Frontiers in psychiatry. 2023 Feb 24;14:1131335.
42. Zięba S, Maciejczyk M, Zalewska A. Ethanol-and cigarette smoke-related alterations in oral redox homeostasis. Frontiers in Physiology. 2022 Jan 28;12:793028.
43. Traphagen N, Tian Z, Allen-Gipson D. Chronic ethanol exposure: pathogenesis of pulmonary disease and dysfunction. Biomolecules. 2015 Oct 20;5(4):2840-53.
44. Virgili F, Nenna R, Ben David S, et al. E-cigarettes and youth: an unresolved Public Health concern. Italian journal of pediatrics. 2022 Jun 14;48(1):97.
45. Bailey KL, Samuelson DR, Wyatt TA. Alcohol use disorder: A pre-existing condition for COVID-19?. Alcohol. 2021 Feb 1;90:11-7.
46. Patel A. Alcohol Use Disorder and Critical Illness. In Substance Use Disorders in Adult Critically Ill Patients 2024 Oct 25 (pp. 27-37). Cham: Springer Nature Switzerland.
47. Kaphalia L, Calhoun WJ. Alcoholic lung injury: metabolic, biochemical and immunological aspects. Toxicology Letters. 2013 Oct 24;222(2):171-9.
48. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proceedings of the American Thoracic Society. 2005 Dec;2(5):428-32.
49. Teschke R, Neuman MG, Liangpunsakul S, et al. Alcoholic Liver Disease and the co-triggering Role of MEOS with Its CYP 2 E 1 Catalytic Cycle and ROS. Archives of Gastroenterology Research. 2021 Feb 16;2(1):9-25.
50. Juan CA, Pérez de la Lastra JM, Plou FJ, et al. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. International journal of molecular sciences. 2021 Apr 28;22(9):4642.
51. Iciek M, Bilska-Wilkosz A, Kozdrowicki M, et al. Reactive sulfur compounds in the fight against COVID-19. Antioxidants. 2022 May 26;11(6):1053.
52. Schumacker PT. Lung cell hypoxia: role of mitochondrial reactive oxygen species signaling in triggering responses. Proceedings of the American Thoracic Society. 2011 Nov 1;8(6):477-84.
53. Cho HY, Kleeberger SR. Mitochondrial biology in airway pathogenesis and the role of NRF2. Archives of pharmacal research. 2020 Mar;43(3):297-320.
54. Le Dare B, Lagente V, Gicquel T. Ethanol and its metabolites: update on toxicity, benefits, and focus on immunomodulatory effects. Drug metabolism reviews. 2019 Oct 2;51(4):545-61.
55. Da Cruz Nizer WS, Inkovskiy V, et al. Oxidative stress response in Pseudomonas aeruginosa. Pathogens. 2021 Sep 14;10(9):1187.
56. Crotty K. *Alveolar Macrophage Oxidative Stress and Metabolic Dysfunction During Chronic Alcohol Use* (Doctoral dissertation, Emory University).
57. Luyt CE, Bouadma L, Morris AC, et al. Pulmonary infections complicating ARDS. Intensive care medicine. 2020 Dec;46(12):2168-83.
58. Wang X, Chen X, Lu L, et al. Alcoholism and osteoimmunology. Current medicinal chemistry. 2021 Mar 1;28(9):1815-28.
59. Ng TS, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Frontiers in immunology. 2013 May 31;4:129.
60. Nowak AJ, Relja B. The impact of acute or chronic alcohol intake on the NF-κB signaling pathway in alcohol-related liver disease. International Journal of Molecular Sciences. 2020 Dec 10;21(24):9407.
61. Trevejo-Nunez G, Kolls JK, De Wit M. Alcohol use as a risk factor in infections and healing: a clinician's perspective. Alcohol research: current reviews. 2015;37(2):177.
62. Kershaw CD, Guidot DM. Alcoholic lung disease. Alcohol Research & Health. 2008;31(1):66.
63. Joshi PC, Guidot DM. The alcoholic lung: epidemiology, pathophysiology, and potential therapies. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2007 Apr;292(4):L813-23.

64. Mehta AJ. Alcoholism and critical illness: A review. World J Crit Care Med. 2016 Feb 4;5(1):27-35. doi: 10.5492/wjccm.v5.i1.27. PMID: 26855891; PMCID: PMC4733453.
65. Berner MM, Kriston L, Bentele M,et al. The alcohol use disorders identification test for detecting at-risk drinking: a systematic review and meta-analysis. Journal of studies on alcohol and drugs. 2007 May;68(3):461-73.
66. Wigger GW, Bouton TC, Jacobson KR, Auld SC, Yeligar SM, Staitieh BS. The impact of alcohol use disorder on tuberculosis: a review of the epidemiology and potential immunologic mechanisms. Frontiers in immunology. 2022 Mar 31;13:864817.
67. Ramadori GP. Organophosphorus poisoning: Acute respiratory distress syndrome (ARDS) and cardiac failure as cause of death in hospitalized patients. International journal of molecular sciences. 2023 Apr 3;24(7):6658.
68. Sisson JH. Alcohol and airways function in health and disease. Alcohol. 2007 Aug 1;41(5):293-307.
69. Albert RK. Constant Vt ventilation and surfactant dysfunction: an overlooked cause of ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine. 2022 Jan 15;205(2):152-60.
70. Seaman EL. *Co-Occurring Tobacco and Marijuana Use Among Young Adults: A Sequential Explanatory Mixed Methods Study* (Doctoral dissertation, University of Maryland, College Park).
71. Babor TE, Higgins-Biddle J, Dauser D, et al. Alcohol screening and brief intervention in primary care settings: implementation models and predictors. Journal of studies on alcohol. 2005 May;66(3):361-8.
72. Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. BMJ open. 2018 Aug 1;8(8):e022344.
73. Guidot DM, Roman J. Chronic ethanol ingestion increases susceptibility to acute lung injury: role of oxidative stress and tissue remodeling. Chest. 2002 Dec 1;122(6):309S-14S.
74. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Research & Health. 2007;30(1):5.
75. Moss M, Burnham EL. Chronic alcohol abuse, acute respiratory distress syndrome, and multiple organ dysfunction. Critical care medicine. 2003 Apr 1;31(4):S207-12.
76. Guidot DM, Hart MC. Alcohol abuse and acute lung injury: epidemiology and pathophysiology of a recently recognized association. Journal of Investigative Medicine. 2005 Jul;53(5):235-45.
77. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Allen HL, Lindgren CM, Luan JA, Mägi R, Randall JC. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature genetics. 2010 Nov;42(11):937-48.